SCHEMBL4132079

SCHEMBL4132079

OCc1ccc(C2=N[N]N=N2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
TSHR P16473 1/20 0.36
FYN P06241 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
KIF11 P52732 1/20 0.33
MAP2K4 P45985 2/20 0.33
RIPK1 Q13546 1/20 0.33
HDAC2 Q92769 1/20 0.33
PTGS1 P23219 1/20 0.33
VHL P40337 1/20 0.32
ELOC Q15369 1/20 0.32
ELOB Q15370 1/20 0.32
LTA4H P09960 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679970 0.71 MKNK1 (0.56) MKNK1MKNK2TSHRPRSS1PRSS2
SCHEMBL11310791 0.71 MKNK1 (0.56) MKNK1MKNK2TSHRPRSS1PRSS2
SCHEMBL4954440 0.69 MAPT (0.48) TSHRKIF11
SCHEMBL41775 0.68 TSHR (0.67) MKNK1MKNK2TSHRPRSS1PRSS2
SCHEMBL577997 0.67 NQO1 (0.52) TSHRLTA4H
SCHEMBL577887 0.67 CA12 (0.46) PTGS1CA12CA1CA2CA7
Fluoride SCHEMBL28282617 0.65 TSHR (0.62) MKNK1MKNK2TSHRPRSS1PRSS2
SCHEMBL6968521 0.64 CA12 (0.35) MKNK1MKNK2TSHRHDAC2CA12
SCHEMBL1439245 0.64 MKNK1 (0.61) MKNK1MKNK2FYNKIF11CYP11B1
SCHEMBL12092808 0.62 ESR1 (0.61) MKNK1MKNK2TSHRHDAC2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
EP-1423391-B8 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2007-12-12 EP disclosed
EP-1423391-B1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2006-05-17 EP disclosed
US-20050054851-A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2005-03-10 US disclosed
EP-1423391-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES Novartis AG (CH) 2004-06-02 EP disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054851-A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases CTSK, CTSS, CTSZ MKNK1 869/4885MKNK2 917/4885TSHR 4339/4885
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases CTSK, CTSS, CTSZ MKNK1 869/4885MKNK2 917/4885TSHR 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.